Carina Stegmayr1, Ulrike Bandelow2, Dennis Oliveira2, Philipp Lohmann2, Antje Willuweit2, Christian Filss2,3, Norbert Galldiks2, Joachim H R Lübke2, N Jon Shah2,3,4, Johannes Ermert2,3, Karl-Josef Langen5,6. 1. Forschungszentrum Jülich, Institute of Neuroscience and Medicine, D-52425, Jülich, Germany. c.stegmayr@fz-juelich.de. 2. Forschungszentrum Jülich, Institute of Neuroscience and Medicine, D-52425, Jülich, Germany. 3. Department of Nuclear Medicine and Neurology, RWTH/University Hospital Aachen, Aachen, Germany. 4. Jülich-Aachen Research Alliance (JARA) - Section JARA-Brain, Aachen, Germany. 5. Forschungszentrum Jülich, Institute of Neuroscience and Medicine, D-52425, Jülich, Germany. k.j.langen@fz-juelich.de. 6. Department of Nuclear Medicine and Neurology, RWTH/University Hospital Aachen, Aachen, Germany. k.j.langen@fz-juelich.de.
Abstract
PURPOSE: O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on 18F-FET uptake in two rat glioma models and one human xenograft model. METHODS: F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent 18F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of 18F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs. RESULTS: In Dex treated animals EBD extravasation was significantly reduced in 9L (P < 0.001) and U87 (P = 0.008) models and showed a trend in F98 models (P = 0.053). In contrast, no significant differences of 18F-FET uptake were observed between Dex treated animals and control group except a decrease of the TBR in the 9L tumor model in PET (P < 0.01). Ultrastructural evaluation of tumor blood vessel endothelia revealed significant reduction of the cleft diameter between endothelial cells after Dex treatment in F98 model (P = 0.010). CONCLUSION: Despite a considerable reduction of BBB permeability in rat gliomas after Dex treatment, no relevant changes of 18F-FET uptake were noted in this experimental study. Thus, 18F-FET uptake in gliomas appears to be widely independent of the permeability of the BBB.
PURPOSE:O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on 18F-FET uptake in two ratglioma models and one human xenograft model. METHODS:F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent 18F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of 18F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs. RESULTS: In Dex treated animals EBD extravasation was significantly reduced in 9L (P < 0.001) and U87 (P = 0.008) models and showed a trend in F98 models (P = 0.053). In contrast, no significant differences of 18F-FET uptake were observed between Dex treated animals and control group except a decrease of the TBR in the 9L tumor model in PET (P < 0.01). Ultrastructural evaluation of tumor blood vessel endothelia revealed significant reduction of the cleft diameter between endothelial cells after Dex treatment in F98 model (P = 0.010). CONCLUSION: Despite a considerable reduction of BBB permeability in ratgliomas after Dex treatment, no relevant changes of 18F-FET uptake were noted in this experimental study. Thus, 18F-FET uptake in gliomas appears to be widely independent of the permeability of the BBB.
Authors: Frank W Floeth; Dirk Pauleit; Michael Sabel; Gabriele Stoffels; Guido Reifenberger; Markus J Riemenschneider; Paul Jansen; Heinz H Coenen; Hans-Jakob Steiger; Karl-Josef Langen Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057
Authors: Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-01 Impact factor: 9.236
Authors: Michael A Badruddoja; Hendrikus G J Krouwer; Scott D Rand; Kelly J Rebro; Arvind P Pathak; Kathleen M Schmainda Journal: Neuro Oncol Date: 2003-10 Impact factor: 12.300
Authors: Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Mette K Nedergaard; Karina Kristoffersen; Signe R Michaelsen; Jacob Madsen; Hans S Poulsen; Marie-Thérése Stockhausen; Ulrik Lassen; Andreas Kjaer Journal: PLoS One Date: 2014-06-11 Impact factor: 3.240
Authors: N A da Silva; P Lohmann; J Fairney; A W Magill; A-M Oros Peusquens; C-H Choi; R Stirnberg; G Stoffels; N Galldiks; X Golay; K-J Langen; N Jon Shah Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-24 Impact factor: 9.236